According to GuruFocus Insider Data, the recent chief financial officer buys were Tilray Inc. (TLRY, Financial), Investors Real Estate Trust (IRET, Financial) and Provention Bio Inc. (PRVB, Financial).
Tilray CFO bought 14,705 shares
CFO, Secretary and Treasurer Mark Castaneda bought 14,705 shares for $17 per share on July 23. Since then, the stock price has increased by 55.29%.
Tilray has a market cap of $2.42 billion and its shares were traded around $26.40.
The company announced its first-quarter results with revenue of $7.81 million and gross profit of $3.90 million, while the net loss was $5.18 million. Total revenue in 2017 was $20.54 million, a 62% increase from 2016. The gross profit was $11.38 million, a 326% increase from the year prior. The net loss was $7.81 million.
President and CEO Brendan Kennedy bought 14,706 shares for $17 per share on July 23, and Chief Revenue Officer Edward Wood Pastorius Jr. bought 14,705 shares. Since then, the stock price has increased by 55.29%.
Investors Real Estate Trust CFO bought 10,846 shares
Executive Vice President and CFO John Kirchmann bought 7,034 shares for $5.32 per share on July 24. Since then, the stock price has gained 3.2%.
Investors Real Estate Trust has a market cap of $655.550 million and its shares were traded around $5.49. The company has a price-earnings ratio of 6.32 and a price-sales ratio of 3.81. The trailing 12-month dividend yield is 5.11%, while the forward dividend yield is 5.13%.
The company announced its second-quarter results with revenue of $42.37 million and gross profit of $24.64 million, while the net loss was $20.87 million. The 2018 total revenue was $169.75 million, a 6% increase from 2017. The gross profit was $91.13 million, a 4% increase from the year prior. The net loss was $116.79 million.
President, CEO and Chief Investment Officer Mark Okey Decker Jr. bought 650 shares for $5.37 per share on July 20. Since then, the stock price has risen 2.23%.
Provention Bio CFO bought 6,250 shares
CFO Andrew T. Drechsler bought 6,250 shares for $4 per share on July 19. Since then, the stock price has climbed 11.25%.
Provention Bio has a market cap of $150.790 million and its shares were traded around $4.45.
President and CEO Ashleigh Palmer bought 37,500 shares for $4 per share on July 19, while Director Wayne Pisano bought 2,500 shares and Chief Scientific Officer Francisco Leon bought 37,500 shares. Since then, the stock price has risen 11.25%.
Disclosure: None.Â
